Trial reportPsychoneuroendocrinology2016
Stress management, leukocyte transcriptional changes and breast cancer recurrence in a randomized trial: An exploratory analysis.
Trial report in Psychoneuroendocrinology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.
- Mind-body interventions for fear of cancer recurrence: A systematic review and meta-analysis.Psycho-oncology · 2018Pooled it
- An extraverted behavior intervention improves immune gene expression.Brain, behavior, and immunity · 2026Trial
- Brief Post-Surgical Stress Management Reduces Pro-Inflammatory Cytokines in Overweight and Obese Breast Cancer Patients Undergoing Primary Treatment.Frontiers in bioscience (Landmark edition) · 2022Trial
- Effects of web-based cognitive behavioral stress management and health promotion interventions on neuroendocrine and inflammatory markers in men with advanced prostate cancer: A randomized controlled trial.Brain, behavior, and immunity · 2021Trial
- Effects of brief stress management interventions on distress and leukocyte nuclear factor kappa B expression during primary treatment for breast cancer: A randomized trial.Psychoneuroendocrinology · 2021Trial
- Trial
- Chronic stress and cancer progression through neuro‑endocrine‑immune networks (Review).Oncology reports · 2026Review
- Hiding in plain sight: Cooperative Extension as an underutilized approach to improving cancer survivorship outcomes in underserved populations.Journal of cancer survivorship : research and practice · 2026Article
- Beyond survival: psychoneuroimmunology-driven cancer psychological rehabilitation-a paradigm shift from symptom management to biobehavioral remodeling.Frontiers in oncology · 2026Review
- Neighborhood deprivation, breast cancer outcomes and stress-related gene expression in leukocytes and tumor tissue.Breast cancer research : BCR · 2025Article
- Distinct Sources of Social Adversity, Stress, and Coping Mechanisms among Patients with Breast Cancer to Identify Areas for Intervention.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Parasympathetic nervous activity and CTRA gene expression among healthy young adults in Japan.Brain, behavior, & immunity - health · 2025Article
- Socioeconomic status impacts tumor biology, treatment, and outcomes in over 200,000 patients with invasive lobular carcinoma of the breast: an analysis of the National Cancer Database.Breast cancer research and treatment · 2025Article
- Geospatial Genomics: Operationalizing Multilevel Conceptual Frameworks of Cancer Health Outcomes to Account for Gene-Person-Place Relationships.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- Gerotherapeutics: aging mechanism-based pharmaceutical and behavioral interventions to reduce cancer racial and ethnic disparities.Journal of the National Cancer Institute · 2025Review
- Preliminary evaluation of a mindfulness intervention program in women with long COVID dysautonomia symptoms.Brain, behavior, & immunity - health · 2025Article
- Genome-wide transcriptome differences associated with perceived discrimination in an urban, community-dwelling middle-aged cohort.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Transcriptomics and psychotherapy: An integrative review.Brain, behavior, & immunity - health · 2024Review
- ZIP Code to Genomic Code: Neighborhood Disadvantage, Aggressive Breast Cancer Biology, and Breast Cancer Outcomes.Annals of surgery · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
purposeCognitive behavioral stress management (CBSM) is an empirically-validated group-based psychosocial intervention. CBSM is related to decreased self-reported indicators of psychological adversity during breast cancer treatment and greater disease-free survival (DFS) vs. a control condition. This study examined relationships between CBSM, DFS, and a potential biobehavioral pathway linking these variables in breast cancer patients through a gene expression composite representing the leukocyte conserved transcriptional response to adversity (CTRA).
designWomen with stage 0-IIIb breast cancer completed questionnaires and provided blood samples post-surgery. Participants were randomized to 10-week group-based CBSM or a psychoeducation control group and followed at 6 months, 12 months, and median 11 years. In total, 51 participants provided blood data for longitudinal analyses (CBSM n=28; Control n=23). Mixed model analyses examined CBSM effects on 6-12 month changes in CTRA expression (53 indicator genes representing pro-inflammatory, anti-viral and antibody production signaling). Cox regression models assessed the relationship between 6 and 12 month changes in CTRA expression and 11-year DFS.
resultsPatients randomized to CBSM showed attenuated 6-12 month change in CTRA gene expression, whereas patients randomized to control showed increased CTRA expression (p=0.014). Average DFS was 5.92 years (SD=3.90). Greater 6-12 month CTRA increases predicted shorter 11-year DFS controlling for covariates (p=0.007).
conclusionsCBSM attenuated CTRA gene expression during the initial year of breast cancer treatment. In turn, greater increases in CTRA gene expression predicted shorter long-term DFS. These findings identify a biobehavioral oncology pathway to examine in future work.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.